Aromatase inhibitors for therapy of advanced breast cancer
- 31 May 2005
- journal article
- research article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 95 (1-5) , 113-119
- https://doi.org/10.1016/j.jsbmb.2005.04.014
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer, 2001
- Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol AcetateJournal of Clinical Oncology, 2001
- Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2001
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized TrialJournal of Clinical Oncology, 2000
- Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability StudyJournal of Clinical Oncology, 2000
- Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind TrialJournal of Clinical Oncology, 2000
- Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinomaCancer, 1998
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinomaCancer, 1997
- A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *European Journal Of Cancer, 1996